Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Payables (2021 - 2025)

Prime Medicine filings provide 5 years of Payables readings, the most recent being $8.9 million for Q4 2025.

  • On a quarterly basis, Payables fell 21.71% to $8.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.9 million, a 21.71% decrease, with the full-year FY2025 number at $8.9 million, down 21.71% from a year prior.
  • Payables hit $8.9 million in Q4 2025 for Prime Medicine, down from $9.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $19.5 million in Q4 2023 to a low of $1.4 million in Q4 2021.
  • Median Payables over the past 5 years was $6.4 million (2025), compared with a mean of $8.0 million.
  • Biggest five-year swings in Payables: surged 350.99% in 2023 and later tumbled 61.56% in 2024.
  • Prime Medicine's Payables stood at $1.4 million in 2021, then surged by 201.88% to $4.3 million in 2022, then surged by 350.99% to $19.5 million in 2023, then plummeted by 41.9% to $11.4 million in 2024, then fell by 21.71% to $8.9 million in 2025.
  • The last three reported values for Payables were $8.9 million (Q4 2025), $9.4 million (Q3 2025), and $6.4 million (Q2 2025) per Business Quant data.